PT3050564T - Pró-fármacos éster de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanol - Google Patents
Pró-fármacos éster de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanolInfo
- Publication number
- PT3050564T PT3050564T PT161619234T PT16161923T PT3050564T PT 3050564 T PT3050564 T PT 3050564T PT 161619234 T PT161619234 T PT 161619234T PT 16161923 T PT16161923 T PT 16161923T PT 3050564 T PT3050564 T PT 3050564T
- Authority
- PT
- Portugal
- Prior art keywords
- imidazol
- methylphenyl
- drugs
- methanol
- ethyl
- Prior art date
Links
- HTQCEFAVROSRIW-UHFFFAOYSA-N [3-[1-(1h-imidazol-5-yl)ethyl]-2-methylphenyl]methanol Chemical compound C=1C=CC(CO)=C(C)C=1C(C)C1=CNC=N1 HTQCEFAVROSRIW-UHFFFAOYSA-N 0.000 title 1
- 150000002148 esters Chemical class 0.000 title 1
- 229940002612 prodrug Drugs 0.000 title 1
- 239000000651 prodrug Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38337010P | 2010-09-16 | 2010-09-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3050564T true PT3050564T (pt) | 2019-12-11 |
Family
ID=44675870
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT161619234T PT3050564T (pt) | 2010-09-16 | 2011-09-16 | Pró-fármacos éster de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanol |
| PT16161920T PT3050563T (pt) | 2010-09-16 | 2011-09-16 | Pró-fármacos de éster de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil] metanol para o tratamento de doenças e afeções da pele |
| PT117609628T PT2616068T (pt) | 2010-09-16 | 2011-09-16 | Pró-fármacos ésteres de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanol para abaixamento da pressão intraocular |
| PT181601741T PT3348264T (pt) | 2010-09-16 | 2011-09-16 | Pró-fármacos ésteres de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanol para abaixamento da pressão intraocular |
| PT16161922T PT3053576T (pt) | 2010-09-16 | 2011-09-16 | Pró-fármacos ésteres de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanol para redução da pressão intraocular |
| PT181571472T PT3338777T (pt) | 2010-09-16 | 2011-09-16 | Pró-fármacos ésteres de [3-(1-(1h-imidazol-4- il)etil)-2-metilfenil]metanol para tratamento de doenças retinianas |
| PT117609636T PT2616069T (pt) | 2010-09-16 | 2011-09-16 | Pró-fármacos éster de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanol |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT16161920T PT3050563T (pt) | 2010-09-16 | 2011-09-16 | Pró-fármacos de éster de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil] metanol para o tratamento de doenças e afeções da pele |
| PT117609628T PT2616068T (pt) | 2010-09-16 | 2011-09-16 | Pró-fármacos ésteres de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanol para abaixamento da pressão intraocular |
| PT181601741T PT3348264T (pt) | 2010-09-16 | 2011-09-16 | Pró-fármacos ésteres de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanol para abaixamento da pressão intraocular |
| PT16161922T PT3053576T (pt) | 2010-09-16 | 2011-09-16 | Pró-fármacos ésteres de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanol para redução da pressão intraocular |
| PT181571472T PT3338777T (pt) | 2010-09-16 | 2011-09-16 | Pró-fármacos ésteres de [3-(1-(1h-imidazol-4- il)etil)-2-metilfenil]metanol para tratamento de doenças retinianas |
| PT117609636T PT2616069T (pt) | 2010-09-16 | 2011-09-16 | Pró-fármacos éster de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanol |
Country Status (28)
| Country | Link |
|---|---|
| US (9) | US8492557B2 (enExample) |
| EP (13) | EP2616066B1 (enExample) |
| JP (4) | JP6045495B2 (enExample) |
| KR (7) | KR101840501B1 (enExample) |
| CN (5) | CN105412092B (enExample) |
| AR (4) | AR083019A1 (enExample) |
| AU (4) | AU2011301847B2 (enExample) |
| BR (4) | BR112013006352A2 (enExample) |
| CA (8) | CA2811559A1 (enExample) |
| CL (4) | CL2013000736A1 (enExample) |
| CY (3) | CY1121024T1 (enExample) |
| DK (9) | DK3050563T3 (enExample) |
| ES (10) | ES2687420T3 (enExample) |
| HU (5) | HUE048725T2 (enExample) |
| IL (4) | IL225281A0 (enExample) |
| MX (4) | MX2013003009A (enExample) |
| MY (4) | MY168763A (enExample) |
| NZ (1) | NZ608751A (enExample) |
| PL (7) | PL3050563T3 (enExample) |
| PT (7) | PT3050564T (enExample) |
| RU (4) | RU2013116763A (enExample) |
| SG (4) | SG188573A1 (enExample) |
| SI (5) | SI3050564T1 (enExample) |
| TR (1) | TR201909249T4 (enExample) |
| TW (4) | TW201240661A (enExample) |
| UA (1) | UA112973C2 (enExample) |
| WO (4) | WO2012037453A1 (enExample) |
| ZA (4) | ZA201302194B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010093930A1 (en) | 2009-02-13 | 2010-08-19 | Allergan, Inc. | Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol |
| JP6196041B2 (ja) | 2010-01-11 | 2017-09-13 | オレキシジェン・セラピューティクス・インコーポレーテッド | 大うつ病を有する患者において減量療法を提供する方法 |
| US8492557B2 (en) * | 2010-09-16 | 2013-07-23 | Allergan, Inc. | Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol |
| CA2842866A1 (en) * | 2011-07-22 | 2013-01-31 | Allergan, Inc. | Alpha-2 adrenergic modulators for treating visual disorders mediated by central visual projections from the eye |
| WO2013078151A1 (en) | 2011-11-21 | 2013-05-30 | Allergan, Inc. | Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3h-imidazole derivatives for treating retinal diseases |
| USD794650S1 (en) | 2014-11-28 | 2017-08-15 | Samsung Electronics Co., Ltd. | Display screen or portion thereof with a graphical user interface |
| CN108310442B (zh) * | 2017-01-17 | 2021-08-27 | 台北科技大学 | 眼科用组合物 |
| KR102050506B1 (ko) | 2017-06-20 | 2019-11-29 | 한국식품연구원 | 망막 질환 예방, 개선, 완화 또는 치료용 조성물 |
| CN108872431B (zh) * | 2018-07-09 | 2021-03-23 | 成都倍特药业股份有限公司 | 一种检测4-(1-(2,5-二甲基苯基)乙基)-1h-咪唑或/和其盐酸盐的方法 |
| CN111386275B (zh) * | 2018-08-24 | 2023-03-10 | 杭州阿诺生物医药科技有限公司 | 高活性sting蛋白激动剂 |
| CA3214876A1 (en) * | 2021-04-16 | 2022-10-20 | Wenkui Ken Fang | Alpha2 adrenergic agonist codrugs conjugated with muscarinic agonist drugs |
| EP4661868A1 (en) * | 2023-02-08 | 2025-12-17 | Bausch + Lomb Ireland Limited | Alpha-2-adrenergic agonists for improving vision |
| WO2025179071A1 (en) * | 2024-02-20 | 2025-08-28 | Bausch + Lomb Ireland Limited | Sustained-release drug delivery compositions for treating ocular diseases |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG45449A1 (en) | 1992-05-13 | 1998-01-16 | Sandoz Ltd | Ophthalmic compositions |
| US5459133A (en) * | 1992-06-05 | 1995-10-17 | Telor Ophthalmic Pharmaceuticals, Inc. | Methods and products for treating presbyopia |
| ES2188649T3 (es) | 1993-11-15 | 2003-07-01 | Schering Corp | Fenil-alquil-imidazoles como antagonistas del receptor h3. |
| US5474979A (en) | 1994-05-17 | 1995-12-12 | Allergan, Inc. | Nonirritating emulsions for sensitive tissue |
| EP0957073A1 (en) * | 1998-05-12 | 1999-11-17 | Schwarz Pharma Ag | Novel derivatives of 3,3-diphenylpropylamines |
| US20040214829A1 (en) * | 2000-07-14 | 2004-10-28 | Allergan, Inc. | Compositions containing alpha-2-adrenergic agonist components |
| US20020198209A1 (en) | 2001-05-03 | 2002-12-26 | Allergan Sales Inc. | Compositions having enhanced pharmacokinetic characteristics |
| US7439241B2 (en) * | 2003-05-27 | 2008-10-21 | Galderma Laboratories, Inc. | Compounds, formulations, and methods for treating or preventing rosacea |
| WO2004106307A2 (fr) * | 2003-05-27 | 2004-12-09 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Nouveaux derives d’imidazoles, leur preparation et leur utilisation en tant que medicament |
| WO2005006720A1 (en) * | 2003-07-14 | 2005-01-20 | Koninklijke Philips Electronics N.V. | Projection device |
| CA2538445A1 (en) * | 2003-09-12 | 2005-04-21 | Allergan, Inc. | Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
| US20050059583A1 (en) | 2003-09-15 | 2005-03-17 | Allergan, Inc. | Methods of providing therapeutic effects using cyclosporin components |
| US20050244463A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular vasculopathies |
| DK1761266T3 (da) * | 2004-05-25 | 2013-08-05 | Galderma Pharma Sa | Forbindelser, formuleringer og fremgangsmåder til at behandle eller forebygge inflammatoriske hudsygdomme |
| US20050277584A1 (en) | 2004-06-09 | 2005-12-15 | Allergan, Inc. | Pharmaceutical compositions comprising cyclosporins |
| JP2008514601A (ja) * | 2004-09-24 | 2008-05-08 | アラーガン、インコーポレイテッド | 特異的α２アドレナリン作動剤としての４−（フェニルメチルおよび置換フェニルメチル）−イミダゾール−２−チオン |
| US7931909B2 (en) | 2005-05-10 | 2011-04-26 | Allergan, Inc. | Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates |
| US7297679B2 (en) | 2005-07-13 | 2007-11-20 | Allergan, Inc. | Cyclosporin compositions |
| US20070015691A1 (en) | 2005-07-13 | 2007-01-18 | Allergan, Inc. | Cyclosporin compositions |
| US20070082070A1 (en) * | 2005-10-11 | 2007-04-12 | Stookey Evangeline L | Treating skin disorders |
| US7902247B2 (en) | 2008-01-09 | 2011-03-08 | Allergan, Inc. | Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors |
| AU2010210513A1 (en) | 2009-02-06 | 2011-09-01 | Allergan, Inc. | Pyridine compounds as subtype selective modulators of alpha2B and/or alpha 2C adrenergic receptors |
| WO2010093930A1 (en) | 2009-02-13 | 2010-08-19 | Allergan, Inc. | Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol |
| US8394800B2 (en) * | 2009-11-19 | 2013-03-12 | Galderma Laboratories, L.P. | Method for treating psoriasis |
| US8492557B2 (en) * | 2010-09-16 | 2013-07-23 | Allergan, Inc. | Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol |
-
2011
- 2011-09-15 US US13/233,891 patent/US8492557B2/en active Active
- 2011-09-15 US US13/233,844 patent/US8501796B2/en active Active
- 2011-09-15 US US13/233,382 patent/US8653123B2/en active Active
- 2011-09-15 US US13/233,665 patent/US8492422B2/en active Active
- 2011-09-16 ES ES16161920.0T patent/ES2687420T3/es active Active
- 2011-09-16 UA UAA201304644A patent/UA112973C2/uk unknown
- 2011-09-16 HU HUE18157147A patent/HUE048725T2/hu unknown
- 2011-09-16 KR KR1020137009503A patent/KR101840501B1/ko active Active
- 2011-09-16 EP EP11760958.6A patent/EP2616066B1/en active Active
- 2011-09-16 CA CA2811559A patent/CA2811559A1/en active Pending
- 2011-09-16 JP JP2013529372A patent/JP6045495B2/ja active Active
- 2011-09-16 AU AU2011301847A patent/AU2011301847B2/en active Active
- 2011-09-16 KR KR1020207021626A patent/KR102354097B1/ko active Active
- 2011-09-16 EP EP18160174.1A patent/EP3348264B1/en active Active
- 2011-09-16 DK DK16161920.0T patent/DK3050563T3/en active
- 2011-09-16 SG SG2013019591A patent/SG188573A1/en unknown
- 2011-09-16 DK DK16161923T patent/DK3050564T3/da active
- 2011-09-16 NZ NZ60875111A patent/NZ608751A/en unknown
- 2011-09-16 EP EP16161921.8A patent/EP3078376B1/en active Active
- 2011-09-16 SI SI201131819T patent/SI3050564T1/sl unknown
- 2011-09-16 EP EP16161920.0A patent/EP3050563B1/en active Active
- 2011-09-16 MX MX2013003009A patent/MX2013003009A/es active IP Right Grant
- 2011-09-16 MY MYPI2013000931A patent/MY168763A/en unknown
- 2011-09-16 PT PT161619234T patent/PT3050564T/pt unknown
- 2011-09-16 ES ES11760963.6T patent/ES2613509T3/es active Active
- 2011-09-16 PT PT16161920T patent/PT3050563T/pt unknown
- 2011-09-16 AR ARP110103391A patent/AR083019A1/es unknown
- 2011-09-16 EP EP19217499.3A patent/EP3698789A1/en not_active Withdrawn
- 2011-09-16 DK DK18157147.2T patent/DK3338777T3/da active
- 2011-09-16 TR TR2019/09249T patent/TR201909249T4/tr unknown
- 2011-09-16 AR ARP110103392A patent/AR083020A1/es unknown
- 2011-09-16 ES ES11760962.8T patent/ES2607084T3/es active Active
- 2011-09-16 PL PL16161920T patent/PL3050563T3/pl unknown
- 2011-09-16 CN CN201510767798.7A patent/CN105412092B/zh active Active
- 2011-09-16 MX MX2013003004A patent/MX2013003004A/es active IP Right Grant
- 2011-09-16 ES ES18160174T patent/ES2781681T3/es active Active
- 2011-09-16 TW TW100133488A patent/TW201240661A/zh unknown
- 2011-09-16 WO PCT/US2011/051926 patent/WO2012037453A1/en not_active Ceased
- 2011-09-16 HU HUE18160174A patent/HUE049573T2/hu unknown
- 2011-09-16 AU AU2011301856A patent/AU2011301856C1/en active Active
- 2011-09-16 DK DK19194325.7T patent/DK3636263T3/da active
- 2011-09-16 KR KR1020207011231A patent/KR102139905B1/ko active Active
- 2011-09-16 KR KR1020137009506A patent/KR101952457B1/ko active Active
- 2011-09-16 ES ES16161922.6T patent/ES2684055T3/es active Active
- 2011-09-16 RU RU2013116763/15A patent/RU2013116763A/ru not_active Application Discontinuation
- 2011-09-16 MY MYPI2013000932A patent/MY161607A/en unknown
- 2011-09-16 TW TW100133491A patent/TWI591058B/zh active
- 2011-09-16 PT PT117609628T patent/PT2616068T/pt unknown
- 2011-09-16 PT PT181601741T patent/PT3348264T/pt unknown
- 2011-09-16 DK DK11760963.6T patent/DK2616069T3/en active
- 2011-09-16 PL PL18157147T patent/PL3338777T3/pl unknown
- 2011-09-16 ES ES16161923T patent/ES2760920T3/es active Active
- 2011-09-16 KR KR1020137009505A patent/KR20140005154A/ko not_active Withdrawn
- 2011-09-16 DK DK11760962.8T patent/DK2616068T3/en active
- 2011-09-16 MX MX2013003008A patent/MX2013003008A/es active IP Right Grant
- 2011-09-16 MY MYPI2013000930A patent/MY191369A/en unknown
- 2011-09-16 WO PCT/US2011/052004 patent/WO2012037499A1/en not_active Ceased
- 2011-09-16 JP JP2013529373A patent/JP6073229B2/ja active Active
- 2011-09-16 CN CN201180053886.0A patent/CN103200941B/zh active Active
- 2011-09-16 WO PCT/US2011/051990 patent/WO2012037490A1/en not_active Ceased
- 2011-09-16 CA CA3077732A patent/CA3077732A1/en active Pending
- 2011-09-16 KR KR1020137009502A patent/KR101840500B1/ko active Active
- 2011-09-16 BR BR112013006352A patent/BR112013006352A2/pt not_active IP Right Cessation
- 2011-09-16 EP EP18157147.2A patent/EP3338777B1/en active Active
- 2011-09-16 AU AU2011301901A patent/AU2011301901B2/en active Active
- 2011-09-16 MX MX2013003002A patent/MX2013003002A/es active IP Right Grant
- 2011-09-16 MY MYPI2013000907A patent/MY173846A/en unknown
- 2011-09-16 PL PL11760963T patent/PL2616069T3/pl unknown
- 2011-09-16 CA CA3116249A patent/CA3116249A1/en active Pending
- 2011-09-16 SG SG2013019567A patent/SG188571A1/en unknown
- 2011-09-16 PL PL16161922T patent/PL3053576T3/pl unknown
- 2011-09-16 RU RU2013116541A patent/RU2612351C2/ru active
- 2011-09-16 ES ES16161921T patent/ES2737230T3/es active Active
- 2011-09-16 BR BR112013006362A patent/BR112013006362A2/pt not_active IP Right Cessation
- 2011-09-16 TW TW100133487A patent/TW201305116A/zh unknown
- 2011-09-16 CA CA3122745A patent/CA3122745A1/en active Pending
- 2011-09-16 SI SI201131868T patent/SI3338777T1/sl unknown
- 2011-09-16 CN CN201180053895XA patent/CN103200942A/zh active Pending
- 2011-09-16 PL PL16161923T patent/PL3050564T3/pl unknown
- 2011-09-16 PT PT16161922T patent/PT3053576T/pt unknown
- 2011-09-16 ES ES11760958.6T patent/ES2593612T3/es active Active
- 2011-09-16 SI SI201131547T patent/SI3050563T1/sl unknown
- 2011-09-16 CN CN2011800546049A patent/CN103209694A/zh active Pending
- 2011-09-16 SG SG2013019575A patent/SG188572A1/en unknown
- 2011-09-16 PT PT181571472T patent/PT3338777T/pt unknown
- 2011-09-16 PL PL11760962.8T patent/PL2616068T3/pl unknown
- 2011-09-16 BR BR112013006355A patent/BR112013006355A2/pt not_active IP Right Cessation
- 2011-09-16 DK DK16161922.6T patent/DK3053576T3/en active
- 2011-09-16 CN CN2011800545690A patent/CN103221045A/zh active Pending
- 2011-09-16 EP EP20153104.3A patent/EP3659600A1/en not_active Withdrawn
- 2011-09-16 BR BR112013006320-3A patent/BR112013006320B1/pt active IP Right Grant
- 2011-09-16 ES ES19194325T patent/ES2904479T3/es active Active
- 2011-09-16 AR ARP110103390A patent/AR083018A1/es unknown
- 2011-09-16 RU RU2013116405/15A patent/RU2013116405A/ru unknown
- 2011-09-16 CA CA3079450A patent/CA3079450A1/en active Pending
- 2011-09-16 SI SI201131550T patent/SI3053576T1/sl unknown
- 2011-09-16 HU HUE16161922A patent/HUE039090T2/hu unknown
- 2011-09-16 CA CA2812197A patent/CA2812197C/en active Active
- 2011-09-16 JP JP2013529360A patent/JP2013541527A/ja not_active Withdrawn
- 2011-09-16 EP EP11760963.6A patent/EP2616069B1/en active Active
- 2011-09-16 PT PT117609636T patent/PT2616069T/pt unknown
- 2011-09-16 EP EP11760962.8A patent/EP2616068B1/en active Active
- 2011-09-16 WO PCT/US2011/051979 patent/WO2012037484A1/en not_active Ceased
- 2011-09-16 HU HUE16161920A patent/HUE038698T2/hu unknown
- 2011-09-16 TW TW100133498A patent/TW201240662A/zh unknown
- 2011-09-16 DK DK18160174.1T patent/DK3348264T3/da active
- 2011-09-16 EP EP19194325.7A patent/EP3636263B1/en active Active
- 2011-09-16 EP EP16161923.4A patent/EP3050564B1/en active Active
- 2011-09-16 CA CA2812195A patent/CA2812195A1/en not_active Abandoned
- 2011-09-16 EP EP16161922.6A patent/EP3053576B1/en active Active
- 2011-09-16 DK DK16161921.8T patent/DK3078376T3/da active
- 2011-09-16 HU HUE16161923A patent/HUE047476T2/hu unknown
- 2011-09-16 SI SI201131857T patent/SI3348264T1/sl unknown
- 2011-09-16 CA CA2812191A patent/CA2812191C/en active Active
- 2011-09-16 SG SG2013019559A patent/SG188570A1/en unknown
- 2011-09-16 EP EP11760961.0A patent/EP2616067B1/en active Active
- 2011-09-16 AU AU2011301932A patent/AU2011301932C1/en active Active
- 2011-09-16 ES ES18157147T patent/ES2788051T3/es active Active
- 2011-09-16 AR ARP110103389A patent/AR083017A1/es not_active Application Discontinuation
- 2011-09-16 KR KR1020197004880A patent/KR102104760B1/ko active Active
- 2011-09-16 RU RU2013116403/15A patent/RU2013116403A/ru not_active Application Discontinuation
- 2011-09-16 JP JP2013529371A patent/JP2013537236A/ja not_active Withdrawn
- 2011-09-16 PL PL18160174T patent/PL3348264T3/pl unknown
-
2013
- 2013-03-17 IL IL225281A patent/IL225281A0/en unknown
- 2013-03-17 IL IL225280A patent/IL225280A0/en active IP Right Grant
- 2013-03-17 IL IL225278A patent/IL225278A/en active IP Right Grant
- 2013-03-17 IL IL225282A patent/IL225282A0/en unknown
- 2013-03-18 CL CL2013000736A patent/CL2013000736A1/es unknown
- 2013-03-18 CL CL2013000734A patent/CL2013000734A1/es unknown
- 2013-03-18 CL CL2013000735A patent/CL2013000735A1/es unknown
- 2013-03-18 CL CL2013000733A patent/CL2013000733A1/es unknown
- 2013-03-25 ZA ZA2013/02194A patent/ZA201302194B/en unknown
- 2013-03-25 ZA ZA2013/02193A patent/ZA201302193B/en unknown
- 2013-03-27 ZA ZA2013/02288A patent/ZA201302288B/en unknown
- 2013-03-27 ZA ZA2013/02291A patent/ZA201302291B/en unknown
- 2013-06-13 US US13/916,888 patent/US20130289088A1/en not_active Abandoned
- 2013-06-24 US US13/925,502 patent/US20130296394A1/en not_active Abandoned
- 2013-11-04 US US14/071,090 patent/US8853251B2/en active Active
-
2015
- 2015-01-29 US US14/608,458 patent/US20150148394A1/en not_active Abandoned
-
2016
- 2016-08-18 US US15/240,219 patent/US20160354346A1/en not_active Abandoned
-
2018
- 2018-08-13 CY CY181100852T patent/CY1121024T1/el unknown
-
2020
- 2020-03-20 CY CY20201100265T patent/CY1122958T1/el unknown
- 2020-04-21 CY CY20201100365T patent/CY1122809T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL225278A (en) | Aster drugs of [3 - (1 - (1h - imidazole-4-yl) ethyl) 2-methylphenyl] methanol | |
| SG10201504650VA (en) | Novel Forms Of CDDO Methyl Ester | |
| TWI367034B (en) | Structure of a speaker unit | |
| EP2499151A4 (en) | MAMMALIAN STEROID METABOLITES | |
| IL226384A0 (en) | Pharmaceutical preparations containing (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol | |
| WO2009152493A9 (en) | Use of apolipoproteins to decrease inflammation | |
| HK1163558A (en) | Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl) methanol | |
| HK1165910A (en) | Improvements relating to dc-dc converters |